(MedPage Today) — MADRID — Beta-blockers may be relegated to a smaller role for secondary prevention after myocardial infarction (MI) in contemporary practice, based on the arrival of three new trials from Europe.
Putting aside their known…
Source link : https://www.medpagetoday.com/meetingcoverage/esc/117245
Author :
Publish date : 2025-08-31 17:54:00
Copyright for syndicated content belongs to the linked Source.
